Merck's Lipfendra becomes first oral PCSK9 inhibitor approved by FDA

The US Food and Drug Administration approved Lipfendra (enlicitide) on 16 July 2026, a decision that reshapes how physicians can treat persistently high cholesterol. Manufactured by Merck, known outside the United States and Canada as MSD, the drug is the first oral inhibitor of PCSK9, a protein that governs how efficiently the liver removes LDL, or "bad", cholesterol from the bloodstream. Until now, drugs that target PCSK9 have been available only as subcutaneous injections administered every two to four weeks.

How the drug works, and what the trials showed

Lipfendra belongs to a chemical class called macrocyclic peptides, ring-shaped molecules small enough to survive the digestive system and reach the bloodstream intact. Once there, it binds to PCSK9 and blocks the protein from degrading LDL receptors on liver cells. With more receptors available, the liver clears more LDL from the blood, reducing the cardiovascular risk associated with elevated levels.

The FDA's approval rests on two Phase 3 randomised controlled trials from Merck's CORALreef clinical programme. In CORALreef Lipids, which enrolled adults at high risk of atherosclerotic cardiovascular disease, Lipfendra reduced LDL cholesterol by a placebo-adjusted 56% at week 24. In CORALreef HeFH, which focused on patients with heterozygous familial hypercholesterolemia, an inherited condition that raises cholesterol from birth, the reduction reached 59%. Both outcomes were statistically significant. The drug's safety profile was broadly comparable to placebo across the 3,207 participants enrolled in both studies, with diarrhoea and dizziness reported as the most common side effects in the HeFH trial.

“"High LDL-C is a major risk factor for atherosclerotic cardiovascular disease, which is the leading cause of death globally. Now, for the first time, patients have an oral PCSK9 inhibitor for LDL lowering." — Dr Ann Marie Navar, lead author of the CORALreef Lipids study and associate professor of medicine at UT Southwestern Medical Center”

A significant gap remains: outcomes data

The injectable PCSK9 inhibitors already on the market, evolocumab (Repatha, made by Amgen) and alirocumab (Praluent, by Regeneron and Sanofi), have demonstrated in large cardiovascular outcomes trials that lowering LDL with this mechanism reduces the risk of heart attacks and strokes. Lipfendra has not yet crossed that threshold. Every result so far is a reduction in a cholesterol number, a surrogate for cardiovascular risk, not direct proof of fewer deaths or cardiac events. A dedicated outcomes trial, CORALreef Outcomes, has completed enrolment with over 14,500 participants, but results are not yet available. Until they are, cardiologists will need to weigh the drug's convenience against a longer evidence base for the injectables.

Dosing adds one practical note: Lipfendra must be taken on an empty stomach with water, black coffee, or plain tea, and patients should wait at least 30 minutes before eating or drinking anything else. That requirement may affect adherence for some patients, though clinical trials reported adherence rates above 96%.

Cost and global access will shape real-world impact

Lipfendra's US list price is approximately $315 for a 30-day supply. That is broadly in line with existing injectable PCSK9 inhibitors before rebates and negotiated discounts, though net prices in the United States are typically far lower than list prices once payer negotiations are complete. For international markets, pricing and reimbursement decisions by European and other national health authorities will be critical. Cardiovascular disease already costs EU economies an estimated 210 billion euros per year, according to research cited in clinical literature, and high LDL remains a widely undertreated risk factor: studies suggest that actual use of PCSK9 inhibitors falls far short of the number of patients who qualify for them.

“"By harnessing the innovative science of PCSK9 inhibitors and novel macrocyclic peptide technology, Lipfendra was designed to significantly lower LDL-C in the form of a convenient once-daily pill." — Dr Dean Y. Li, president, Merck Research Laboratories”

Merck received an expedited six-month priority review for the drug under the FDA's Commissioner's National Priority Voucher programme, which accelerates assessment of therapies targeting major public health challenges such as cardiometabolic disease. Whether Lipfendra's approval prompts European regulators at the EMA to fast-track their own review, and at what price national health systems such as NHS England, Germany's GKV, or France's HAS will offer it, will determine how many patients beyond the United States can actually access the drug.

This article is free to read. It always will be — no paywall, no account, no tracking.